Advances in allergen immunotherapy as a treatment of asthma

References

• Nelson HS. Immunotherapy coming of age: notable advances during the first hundred years. Expert Rev Clin Immunol. 2017;13(5):389–392.
   PubMed Web of Science ®Google Scholar
• Walker IC. The treatment of patients with bronchial asthma with subcutaneous injections of the proteins to which they are sensitive. J Med Res. 1917;36(3):423–480.
   PubMedGoogle Scholar
• Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol. 1966;97(1):75–85.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558–562.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Bagnasco D, Ferrando M, et al. Current insights in allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;120(2):152–154.
   PubMed Web of Science ®Google Scholar
• PALISADE Group of Clinical Investigators, BP V, Vereda A, TB C, et al. Oral immunotherapy for peanut allergy. N Engl J Med 2018;379(21):1991–2001.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hellings PW, Agache I, et al. Allergic Rhinitis and its impact on asthma (ARIA) phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019;143(3):864–879.
   PubMed Web of Science ®Google Scholar
• Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.
   PubMed Web of Science ®Google Scholar
• Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 1971;60(3):264–268.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986;16(5):483–491.
   PubMedGoogle Scholar
• Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18(5):277–284.
   PubMed Web of Science ®Google Scholar
• Thacker SB. Meta-analysis. A quantitative approach to research integration. JAMA. 1988;259(11):1685–1689.
   PubMed Web of Science ®Google Scholar
• Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci. 1993;703:156–163.
   PubMed Web of Science ®Google Scholar
• Israel H, Richter RR. A guide to understanding meta-analysis. J Orthop Sports Phys Ther. 2011;41(7):496–504.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2000;2:CD001186.
   Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.
   PubMedGoogle Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
   PubMed Web of Science ®Google Scholar
• Baroffio M, Barisione G, Crimi E, et al. Noninflammatory mechanisms of airway hyper-responsiveness in bronchial asthma: an overview. Ther Adv Respir Dis. 2009;3(4):163–174.
   PubMedGoogle Scholar
• Miller JD. The role of dust mites in allergy. Clin Rev Allergy Immunol. 2018 Jun 23. [Epub ahead of print].
   PubMedGoogle Scholar
• Lu Y, Xu L, Xia M, et al. The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: a meta-analysis. Respir Care. 2015;60(2):269–278.
   PubMed Web of Science ®Google Scholar
• Spertini F, Reymond C, Leimgruber A. Allergen-specific immunotherapy of allergy and asthma: current and future trends. Expert Rev Respir Med. 2009;3(1):37–51.
   PubMedGoogle Scholar
• Hedlin G, van Hage M. The role of immunotherapy in the management of childhood asthma. Ther Adv Respir Dis. 2012;6(3):137–146.
   PubMed Web of Science ®Google Scholar
• Seppälä U, Dauly C, Robinson S, et al. Absolute quantification of allergens from complex mixtures: a new sensitive tool for standardization of allergen extracts for specific immunotherapy. J Proteome Res. 2011;10(4):2113–2122.
   PubMed Web of Science ®Google Scholar
• Carnés J, Iraola V, Cho SH, et al. Mite allergen extracts and clinical practice. Ann Allergy Asthma Immunol. 2017;118(3):249–256.
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy Asthma Proc. 2016;37(1):50–56.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Barberi S, Pastorello E, et al. G. Eur Ann Allergy Clin Immunol. 2019;51(3):115–121.
   PubMedGoogle Scholar
• Wahn U, Bachert C, Heinrich J, et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019;74(3):594–604.
   PubMed Web of Science ®Google Scholar
• Calamita Z, Saconato H, Pelá AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61(10):1162–1172.
   PubMed Web of Science ®Google Scholar
• Penagos M, Passalacqua G, Compalati E, et al. Metanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609.
   PubMed Web of Science ®Google Scholar
• Xu K, Deng Z, Li D, et al. Efficacy of add-on sublingual immunotherapy for adults with asthma: A meta-analysis and systematic review. Ann Allergy Asthma Immunol. 2018;121(2):186–194.
   PubMed Web of Science ®Google Scholar
• Liao W, Hu Q, Shen LL, et al. Sublingual Immunotherapy for asthmatic children sensitized to house dust mite: a meta-analysis. Medicine (Baltimore). 2015;94(24):e701.
   PubMed Web of Science ®Google Scholar
• Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2015 Aug;28(8):CD011293.
   Google Scholar
• Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017;72(12):1825–1848.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30–38.
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once daily grass allergen tablet: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809.
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–1345.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568–575.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725.
   PubMed Web of Science ®Google Scholar
• Canonica GW, J C V, Zieglmayer P, et al. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. Expert Rev Clin Immunol. 2016;12:805–815.
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention; 2017. [cited 2019 May 23]. www.ginasthma.org
   Google Scholar
• Committee on Safety of Medicines. Update: desensitizing vaccines. Br Med J. 1986;293:948.
   PubMedGoogle Scholar
• Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79(4):660–677.
   PubMed Web of Science ®Google Scholar
• Hanci D, Sahin E, Muluk NB, et al. Immunotherapy in all aspects. Eur Arch Otorhinolaryngol. 2016;273(6):1347–1355.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Frati F, Puccinelli P, et al. Dose dependence of efficacy and safety of subcutaneous immunotherapy. Monaldi Arch Chest Dis. 2006;65(1):41–43.
   PubMedGoogle Scholar
• Epstein TG, Liss GM, Murphy-Berendts K, et al. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008-2013). Ann Allergy Asthma Immunol. 2016;116(4):354–359.
   PubMed Web of Science ®Google Scholar
• Epstein TG, Liss GM, Berendts KM, et al. AAAAI/ACAAI subcutaneous immunotherapy surveillance study (2013-2017): fatalities, Infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract. 2019;7(6):1996–2003.
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:24.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Vidal C, Rodríguez Del Río P, EASSI Doctors’ Group, et al. European Survey on adverse systemic reactions in allergen immunotherapy (EASSI): a real-life clinical assessment. Allergy. 2017;72(3):462–472.
   PubMed Web of Science ®Google Scholar
• Aria Workshop Group; World Health Organization, Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–334.
   PubMed Web of Science ®Google Scholar
• Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565–571.
   PubMed Web of Science ®Google Scholar
• Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008;63(3):374.
   PubMed Web of Science ®Google Scholar
• de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64(6):963–964.
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798.
   PubMed Web of Science ®Google Scholar
• Nolte H, Casale TB, Lockey RF, et al. Epinephrine use in clinical trials of sublingual immunotherapy tablets. J Allergy Clin Immunol Pract. 2017;5(1):84–89.
   PubMed Web of Science ®Google Scholar
• Henmar H, Lund G, Lund L, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol. 2008;153(3):316–323.
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Pröll S, Urban E, et al. Single course specific immunotherapy with mixed pollen allergoids: results of a multi-center study. Allergol Immunopathol. 2003;31(2):77–82.
   PubMedGoogle Scholar
• Rosewich M, Schulze J, Eickmeier O, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol. 2010;160(3):403–410.
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Schmutzhard J, van der Werf JF, et al. Efficacy and safety of a glutaraldehydemodified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy. 2010;24(5):104–109.
   Web of Science ®Google Scholar
• Pfaar O, van Twuijver E, Hecker H, et al. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Int Arch Allergy Immunol. 2013;160(4):420–424.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61(7):849–854.
   PubMed Web of Science ®Google Scholar
• Hüser C, Dieterich P, Singh J, et al. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Allergy. 2017;72(1):77–84.
   PubMed Web of Science ®Google Scholar
• Mösges R, Rohdenburg C, Eichel A, et al. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients. Immunotherapy. 2017 Nov;9(15):1225–1238.
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Raskopf E, Shah-Hosseini K, et al. A review of allergoid immunotherapy: is cat allergy a suitable target? Immunotherapy. 2016;8(3):331–349.
   PubMed Web of Science ®Google Scholar
• Dhami S, Agarwal A. Does evidence support the use of cat allergen immunotherapy? Curr Opin Allergy Clin Immunol. 2018;18(4):350–355.
   PubMed Web of Science ®Google Scholar
• Ozdemir C, Kucuksezer UC, Akdis M, et al. Mechanisms of aeroallergen immunotherapy: subcutaneous immunotherapy and sublingual immunotherapy. Immunol Allergy Clin North Am. 2016;36(1):71–86.
   PubMed Web of Science ®Google Scholar
• Stelmach I, Sobocinska A, Majak P, et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy, Asthma Immunol. 2012;109(4):274–278.
   PubMed Web of Science ®Google Scholar